Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Ultrasound Technology to Diagnose and Treat Cardiovascular Disease

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease. Hila Goldman-Aslan says that early detection is the go-to strategy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease.

Hila Goldman-Aslan says that early detection is the go-to strategy to prevent a significant cardiac incident or death. “And ultrasound is the leading modality to identify those abnormalities in the heart, and it’s been increasingly used in all kinds of settings. You can see an ultrasound and cardiac ultrasound being used at the point of care in the emergency rooms and the ICU.”

A 2020 article from the American College of cardiology notes a rise in cardiovascular disease. With one-third of global deaths in 2019 attributed to cardiovascular disease, it is critical to find preventative solutions to reduce these alarming numbers. And this situation is where AI can play an essential role. “Artificial intelligence is all about data,” says Yehudit Levi. “The health segment is unique in the sense that a lot of medical records have been collected through the years. Artificial intelligence software enables processing these masses of data.” The insights gleaned from all this data and knowledge, once made accessible to the medical staff, help highlight abnormalities that might otherwise prove difficult to detect.

DiA Imaging Analysis powered through Intel technology strives to allow for more efficient cardiovascular results and better treatment. “We see physicians looking for more automated procedures and processes to help them make better decisions based on more objective information,” Goldman-Aslan says. Until recently, the review of ultrasound images relied solely on the operator, which creates a layer of subjectivity. With AI analysis, the process becomes more objective and provides better information for the cardiovascular team to make decisions. The increase in cardiac procedures and a shortage of staff analysts available make DiA Imaging ultrasound analysis solutions integral.

“Improving the diagnostic time is super important,” Levi stresses. “It allows more patients to be diagnosed.” Together, DiA and Intel make these ultrasound capabilities scalable for healthcare.

Learn more about Health and Life Sciences by connecting with Yehudit Levi and Hila Goldman-Aslan on LinkedIn or visit: 

 Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512